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Summary
 
B cells from young 
 
lyn
 
2
 
/
 
2
 
 mice are hyperresponsive to anti-IgM–induced proliferation, sug-
gesting involvement of Lyn in negative regulation of B cell antigen receptor (BCR)-mediated
signaling. Here we show that tyrosine phosphorylation of Fc
 
g
 
RIIB and CD22 coreceptors,
which are important for feedback suppression of BCR-induced signaling, was severely im-
paired in 
 
lyn
 
2
 
/
 
2
 
 B cells upon their coligation with the BCR. Hypophosphorylation on tyrosine
residues of these molecules resulted in failure of recruiting the tyrosine phosphatase SHP-1 and
inositol phosphatase SHIP, SH2-containing potent inhibitors of BCR-induced B cell activa-
tion, to the coreceptors. Consequently, 
 
lyn
 
2
 
/
 
2
 
 B cells exhibited defects in suppressing BCR-
induced Ca
 
2
 
1
 
 influx and proliferation. Thus, Lyn is critically important in tyrosine phosphory-
lation of the coreceptors, which is required for feedback suppression of B cell activation.
 
T
 
he Src family protein-tyrosine kinase, Lyn, is highly
expressed in hematopoietic cells. Lyn physically asso-
ciates with the BCR in B cells and with Fc
 
e
 
RI in mast
cells, and is rapidly activated upon cross-linking of the anti-
gen receptors (1–3). Lyn interacts with and phosphorylates
a number of substrates, such as the Syk kinase (4, 5), HS1
protein (6, 7), and Cbl protooncogene product (8). Taken
together, Lyn is thought to play important roles in the anti-
gen receptor–mediated positive signaling.
Recently, however, two groups reported that B cells
from young 
 
lyn
 
2
 
/
 
2
 
 mice were hyperresponsive to anti-
IgM–induced proliferation due in part to the impairment
of Fc
 
g
 
RIIB-mediated feedback suppression of the B cell
antigen receptor (BCR) signaling (9, 10). Therefore, it is
suggested that Lyn may play some roles in the antigen re-
ceptor–mediated negative signaling, too. In this study, us-
ing splenic B cells or bone marrow–derived mast cells
(BMMCs) from 
 
lyn
 
2
 
/
 
2
 
 mice, we addressed molecular
mechanisms by which the Lyn kinase would act as a key
regulator of antigen receptor signaling.
 
Materials and Methods
 
Cells and Cell Culture.
 
All 
 
lyn
 
2
 
/
 
2
 
 mice had been back-crossed
at least six generations to C57BL/6J. Splenic B cells were isolated
from 6–8-wk-old mice by T cell depletion with anti-Thy 1.2
mAb and with rabbit complement, followed by Percoll gradient
purification (11). The resulting cells were 
 
.
 
85% B220
 
1
 
 as deter-
mined by FACS
 
Ò
 
 (Becton Dickinson, Mountain View, CA) anal-
ysis. BMMCs were obtained from bone marrow cells cultured
with IL-3 for at least 4 wk as described (12).
 
Proliferative Responses.
 
For proliferation assay, B cells (10
 
5
 
/
well) were cultured in 96-well flat-bottomed tissue culture plates
either alone or in the presence of goat F(ab
 
9
 
)
 
2
 
 anti-IgM (Cappel,
Durham, NC) or intact anti-IgM (Southern Biotechnology As-
soc., Inc., Birmingham, AL). Cultured cells were pulse-labeled
and assayed as described (13). All assays were performed in tripli-
cate with 
 
,
 
20% variation among assays.
 
Qualification of Total Ig by ELISA.
 
Amounts of each Ig iso-
type in sera and in culture supernatants were determined by
ELISA with antibodies specific for each membrane-bound Ig (mIg)
isotype (13).
 
Immunoprecipitation and Immunoblotting.
 
For the activation of
B cells, splenic B cells were treated with goat F(ab
 
9
 
)
 
2
 
 anti-IgM
(Cappel) or intact anti-IgM (Southern Biotechnology Assoc.,
Inc.) for 2 min at 37
 
8
 
C. For the activation of mast cells, BMMCs
were sensitized for 1 h with antidinitrophenyl (anti-DNP) mono-
clonal IgE (10 
 
m
 
g/ml; Sigma Chemical Co., St. Louis, MO) fol-
lowed by stimulation for 2 min at 37
 
8
 
C with 30 ng/ml DNP-
conjugated human serum albumin (DNP-HSA; resulting in
Fc
 
e
 
RI cross-linking; Sigma Chemical Co.), or DNP-HSA/rabbit
anti-HSA IgG immune complexes (resulting in Fc
 
g
 
RII coliga-
tion to Fc
 
e
 
RI). The stimulated splenic B cells (10
 
7
 
) or BMMCs
(10
 
7
 
) were lysed in TNE (1% [vol/vol] Nonident P-40, 50 mM
Tris-HCl [pH 8], 20 mM EDTA, and 0.2 mM sodium orthovan-
adate with aprotinin at 10 
 
m
 
g/ml) buffer and subjected to immu-
noprecipitation/immunoblotting using SDS-7.5% PAGE as de-
scribed (14). Antibodies used in these experiments were 2.4G2
mAb (PharMingen, San Diego, CA), anti-Fc
 
g
 
RIIB (
 
a
 
-m
 
b
 
1, gift
from J.V. Ravetch, The Rockefeller University, New York),
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anti-CD22 (gift from E.A. Clark, University of Washington, Se-
attle, WA), anti–SHP-1 (Santa Cruz Biotechnology, Santa Cruz,
CA), and anti-SHIP (gift from M.N. Lioubin, Fred Hutchinson
Cancer Research Center, Seattle, WA). Biotinylated 4G10 an-
tiphosphotyrosine antibody (Upstate Biotechnology Inc., Lake
Placid, NY) was used to detect phosphorylated proteins in the
immunoblotting experiments. The blots were treated with horse-
radish peroxidase (HRPO)-streptavidin, and then antibody-reacted
bands were visualized by the use of enhanced chemiluminescence
detection system (Amersham, Co., Arlington Heights, IL).
 
FcR Cross-linking and Degranulation Assay.
 
Fc
 
e
 
RI-triggered mast
cell activation was induced by 1 h of sensitization with 10 
 
m
 
g/ml
biotinylated mouse IgE, followed by cross-linking with 10 
 
m
 
g/ml
streptavidin (0% of Fc
 
g
 
RII coligation). Fc
 
g
 
RII was coligated to
Fc
 
e
 
RI by adding biotinylated anti-Fc
 
g
 
RII monoclonal antibody
(biotin-2.4G2) at the sensitization step (100% of Fc
 
g
 
RII coliga-
tion). A mixture of biotinylated/nonbiotinylated 2.4G2 (1/9 for
10% or 1/99 for 1% coligation) was used to vary the extent of
Fc
 
g
 
RII coligation. The degree of degranulation was determined
by measuring the release of 
 
b
 
-hexosaminidase as described (12).
 
Measurement of Internal Ca
 
2
 
1
 
 Concentration.
 
Splenic B cells and
IgE-sensitized BMMCs from 
 
lyn
 
1
 
/
 
1
 
 and 
 
lyn
 
2
 
/
 
2
 
 mice were incu-
bated with 3 
 
m
 
M Fura-2/acetoxymethyl (AM; Dojindo, Osaka,
Japan) in PBS containing 20 mM Hepes (pH 7.2), 5 mM glucose,
0.025% BSA, and 1 mM CaCl
 
2
 
 at 37
 
8
 
C for 45 min. After the re-
action, the cells were resuspended in 500 
 
m
 
l of the same buffer at
2 
 
3
 
 10
 
6
 
 cells/ml in a stirring cuvette. Then, by using CAF-110
fluorescence spectrophotometer (JASCO, Osaka, Japan), emission
at 500 nm was monitored after excitation of the sample with two
different wavelengths (340 and 380 nm).
 
Results and Discussion
 
lyn
 
2
 
/
 
2
 
 mice, generated by gene targeting, exhibit sple-
nomegaly as they age. The enlarged spleen accumulates un-
Figure 1. (A) Serum levels of IgM and
IgA in unimmunized infant mice. Wild-
type mice (closed circles) and lyn2/2 mice
(open circles) were bled at 0–4 wk of age.
Concentrations of IgM and IgA in their se-
rum were determined by isotype-specific
ELISA (13). Averages of the results from
three experiments are shown. (B) Relative
proliferative responses to BCR cross-link-
ing. Splenic B cells from wild-type (left) or
lyn2/2 (right) mice were cultured with goat
F(ab9)2 anti-IgM (5 mg/ml) or goat intact
anti-IgM (1 or 10 mg/ml). After 42 h of in-
cubation, cells were pulse labeled for 6 h
with [3H]thymidine, and [3H]thymidine in-
corporation was determined (13). All assays
were performed in triplicate. The prolifera-
tive responses were presented with [3H]thy-
midine incorporation expressed as a per-
centage of the response against F(ab9)2 anti-
IgM stimulation.
Figure 2. (A) Anti-IgM–in-
duced tyrosine phosphorylation
of CD22. Splenic B cells were
stimulated with F(ab9)2 anti-IgM
(30 mg/ml) (lanes 3 and 6) or intact
anti-IgM (50 mg/ml) (lanes 2 and
5). Anti-CD22 immunoprecipi-
tates from the cell lysates were
probed with a-PY (phosphoty-
rosine antibody; top) or anti-CD22
antibody (bottom) by immuno-
blotting. (B) Anti-IgM–induced
tyrosine phosphorylation of SHP-1
and its associated molecules.
Splenic B cells were stimulated
with intact anti-IgM (50 mg/ml)
for indicated times. Anti–SHP-1
immunoprecipitates from the cell
lysates were probed with an-
tiphosphotyrosine monoclonal an-
tibody 4G10 (a-PY) by immuno-
blotting. About 150-kD proteins
(upper arrowhead) coimmunopre-
cipitated with SHP-1 (lower ar-
rowhead) corresponded to CD22. 
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usual lymphoblast-like cells and plasma cells (13, 15). 
 
lyn2/2
mice with splenomegaly contain high concentrations of se-
rum IgM and IgA, and often develop glomerulonephritis
due to the production of autoreactive antibodies (13, 15).
The lymphoblast-like cells are IgM1/2, IgD1/2, CD52,
Mac-11, CD232, B2201/2, and IL-5R1/2, and are there-
fore B-1b–like cells. These cells produce spontaneously a
large amount of the antibodies. However, we found that
serum levels of IgM and IgA were extremely high in lyn2/2
mice compared to wild-type mice even at their early ages
(,1 mo old) when the lymphoblast-like cells did not yet
accumulate (Fig. 1 A). This suggests that Lyn is involved in
negative regulation of antibody production by the normal
B cells.
In vitro cross-linking of the BCR on resting B cells in-
duces a proliferative response. The response is prominent
only when F(ab9)2 anti-IgM is used as a stimulating anti-
body, whereas intact anti-IgM fails to fully activate B cells.
This is due to the inhibitory signals induced by coligation
of the BCR and FcgRIIB, a low-affinity immunoglobulin
G receptor (16, 17). In contrast to wild-type B cells, lyn2/2
B cells from young mice (,6 wk old) were highly respon-
sive to the intact anti-IgM, exhibiting a proliferation level
similar to that with F(ab9)2 anti-IgM. The data suggest that
the lyn2/2 B cells are defective in FcgRIIB-mediated sup-
pression of BCR signaling (9, 10, and Fig. 1 B). Furthermore,
the disorders of lyn2/2 mice, such as the hyperresponse to
proliferation after BCR ligation and high concentrations of
serum Igs, are found in mice lacking FcgRIIB (18). More-
over, the phenotypes of mice deficient in SHP-1, an SH2-
containing protein tyrosine phosphatase (19, 20), or CD22,
a B-lineage specific surface molecule (21–24), overlap those
of lyn2/2 mice. Note that both SHP-1 and CD22 partici-
pate in the feedback suppression of BCR signaling, and that
tyrosine phosphorylation of immunoreceptor tyrosine-
based inhibitory motifs (ITIMs; reference 25) of CD22 and
FcgRIIB is involved in the suppression (26–28). The ex-
pression levels of SHP-1, CD22, and FcgRII in lyn2/2
mice did not differ from those in wild-type mice (data not
shown). Therefore, the inhibitory signalings through SHP-1,
CD22, and FcgRIIB are likely related to Lyn kinase activity.
Upon stimulation of the BCR, CD22 and SHP-1 be-
come rapidly tyrosine-phosphorylated (29) and associate
with one another (30–32). To determine whether Lyn is
involved in the tyrosine phosphorylation of CD22 and
SHP-1, we immunoprecipitated these proteins from the ly-
sates of BCR–cross-linked splenic B cells and probed the
immunoprecipitates with antiphosphotyrosine antibody. As
shown in Fig. 2 A, tyrosine phosphorylation of CD22 was
Figure 3. (A) Anti-IgM–induced tyrosine phosphorylation of Fc-
gRIIB. Splenic B cells from wild-type (lanes 1–3), lyn2/2 (lanes 4–6), or
fyn2/2 (lanes 7–9) mice were stimulated with F(ab9)2 anti-IgM (30 mg/ml;
lanes 3, 6, and 9) or intact anti-IgM (50 mg/ml; lanes 2, 5, and 8) for 2
min. Proteins were immunoprecipitated with 2.4G2 anti-FcgRIIB mono-
clonal antibody from the cell lysates, and the precipitates probed with
a-PY (top) or anti-FcgRIIB antibody (a-mb1; bottom) by immunoblot-
ting. (B) Recruitment of SHIP to FcgRIIB. Splenic B cells from wild-
type (lanes 1–3) or lyn2/2 (lanes 4–6) mice were stimulated with F(ab9)2
anti-IgM (30 mg/ml; lanes 3 and 6) or intact anti-IgM (50 mg/ml; lanes 2
and 5) for 2 min. Anti-FcgRIIB (2.4G2) immunoprecipitates from the
cell lysates were probed with anti-SHIP antibodies by immunoblotting.
(C) Time course of Ca21 flux in splenic B cells upon BCR coligation to
FcgRIIB. Panels show real time Fura-2 ratios (340/380) for splenic B
cells of wild-type mice (top) and lyn2/2 mice (bottom). Splenic B cells were
stimulated with F(ab9)2 anti-IgM (5 mg/ml; line), intact anti-IgM (10 mg/
ml; dotted line), or intact anti-IgM (10 mg/ml) in the presence of 1.5 mM
EGTA (perforated line).1346 A Double-edged Kinase Lyn
extremely impaired in lyn2/2 B cells (lanes 5 and 6), as
compared with that in wild-type B cells (lanes 2 and 3). A
level of tyrosine phosphorylation of SHP-1 was also low,
and association of CD22 with SHP-1 was poor in the ab-
sence of Lyn (Fig. 2 B and data not shown).
Next, we examined the level of tyrosine phosphoryla-
tion of anti-FcgRIIB immunoprecipitates prepared from
the lysates of wild-type and lyn2/2 splenic B cells on which
FcgRIIB and BCR had been cross-linked. Immunoblot
analysis of the precipitates with antiphosphotyrosine anti-
body (Fig. 3 A) showed a very low level of tyrosine phos-
phorylation of FcgRIIB in the absence of Lyn. The re-
cruitment of SHIP, an inositol phosphatase important for
the feedback suppression (26–28), from cytoplasm to mem-
brane was also impaired in lyn2/2 B cells (Fig. 3 B). Ac-
cordingly, the magnitude of BCR-induced calcium influx
was less affected by coligated FcgRIIB in lyn2/2 B cells than
in wild-type B cells (Fig. 3 C). Moreover, as mentioned
above, the proliferative response to BCR cross-linking was
not suppressed by coligated FcgRIIB in lyn2/2 B cells (Fig.
1 B). Thus, in the case of B cells, Lyn is directly involved in
the feedback suppression mechanisms as well as in the
BCR positive signaling. The controversial observation that
B cells from relatively older lyn2/2 mice are hyporeactive
to BCR stimulation (13, 15) may suggest that negative sig-
naling pathways are differently tuned with age.
The similarities between the BCR- and FceRI-mediated
signaling prompted us to examine whether tyrosine phos-
phorylation of FcgRIIB coligated with FceRI was im-
paired in lyn2/2 mast cells. As shown in Fig. 4 A, tyrosine
phosphorylation of coligated FcgRIIB was suppressed in
the lyn2/2 BMMCs. This likely results in the failure of re-
cruitment of SHIP and/or SHP-1 to the ITIM of FcgRIIB,
leading to the lack of suppression of FceRI signaling by the
inhibitory coreceptor. However, in both wild-type and
lyn2/2 BMMCs, the calcium response after IgE cross-link-
ing was similarly suppressed by coligation of FcgRIIB with
FceRI–IgE complexes (data not shown). Furthermore,
coligation of FcgRIIB with FceRI–IgE complexes with in-
creasing amounts of the cross-linking antibody resulted in
increasing inhibition of degranulation, as measured by
b-hexosaminidase release, in both wild-type and lyn2/2
BMMCs (Fig. 4 B). Coligation of FcgRIIB with FcgRIII
on both wild-type and lyn2/2 BMMCs also inhibited re-
ceptor-triggered degranulation (the pair columns at the
foremost right in Fig. 4 B). These results suggest that, un-
like the case with the B cells, the negative signaling path-
ways appear to function similarly in wild-type and lyn2/2
BMMCs.
The apparent contradiction between B cells and mast
cells with regard to the FcgRIIB feedback function may be
due to differences in their FcgRIIB-mediated signalings.
Such differences could produce the cell-type specific bal-
ance between the positive and negative signalings. Present
data together with previous observations (9, 10, 12, 13, 15)
indicate that positive signaling is less affected than negative
signaling in lyn2/2 B cells, and vice versa in lyn2/2 mast
cells. The balance of the positive and negative signalings in
lyn2/2 cells could well be influenced by some other Src-
like kinases and Syk kinase expressed in the cells. In B cells,
the imbalance induced by lyn deficiency seems to severely
affect the immune responses. As a consequence, lyn2/2
mice, which have lost the control of positive and negative
signalings, exhibit abnormal phenotypes such as hyperacti-
vation of B cells (9, 10) and elevated serum levels of IgM
and IgA (13, 15), resulting in development of autoimmune
disease (13, 15).
Our data show that Lyn is critically involved in tyrosine
phosphorylation of particular proteins such as CD22 and
FcgRIIB that are involved in the feedback regulation in B
cells and/or BMMCs (for review see references 33–35).
Lyn is also important in tyrosine phosphorylation of immu-
noreceptor tyrosine-based activation motif (ITAM) family
of proteins and the proteins involved in positive regulation
of the BCR and FceRI signaling events (4, 5, 12, 13, 15, 36).
The other membrane molecules with the putative ITIMs
Figure 4. (A) Tyrosine phosphoryla-
tion of FcgRIIB upon FceRI and Fc-
gRIIB coligation. BMMCs from wild-
type (lanes 1–4), lyn2/2 (lanes 5–8) mice
were sensitized with anti-DNP mono-
clonal IgE (10 mg/ml) followed by stim-
ulation for 2 min at 378C with 30 ng/ml
DNP-HSA (FceRI cross-linking; lanes
2 and 6), or DNP-HSA/rabbit anti-
HSA IgG immune complexes (FcgRII
coligation to FceRI; lanes 3 and 7).
BMMCs were stimulated with DNP-
HSA/rabbit anti-HSA IgG immune
complexes without IgE sensitization
(lanes  4 and 8). Anti-FcgRIIB (2.4G2)
immunoprecipitates from the cell ly-
sates were probed with a-PY (top) or
anti-FcgRIIB antibody (a-mb1) (bottom) by immunoblotting. (B) Inhibitory effect of FcgRIIB coligation to FceRI in lyn2/2 BMMCs. The mast cell
was sensitized with biotinylated mouse IgE, followed by cross-linking with streptavidin (no FcgRII coligation). FcgRIIB was coligated to FceRI by add-
ing biotinylated anti-FcgRII monoclonal antibody (biotin-2.4G2) at the sensitization step (100% FcgRII coligation). A mixture of biotinylated/nonbi-
otinylated 2.4G2 (1/9 for 10% or 1/99 for 1% coligation) was used to vary the extent of FcgRII coligation. The degree of degranulation was determined
by measuring the release of b-hexosaminidase as described (12). Closed columns, the results of wild-type mice; open columns, the results of lyn2/2 mice.
Standard errors of triplicate samples are indicated on each column.1347 Nishizumi et al. Brief Definitive Report
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